BUDAPEST, HUNGARY 3/11/09 -- Power of the Dream Ventures, Inc. (OTC BB: PWRV), Hungary's premier technology acquisition and development company, is pleased to present this Genetic Immunity release, based on a previously announced agreement whereby Power of the Dream Ventures will issue communications for Genetic Immunity on a going forward basis.
The DermaPrep Transdermal Delivery Device supports safe, needle-free administration of liquid formulations in both general hospital and clinical settings. To facilitate the penetration of substances, the skin is cleansed and exfoliated prior to application of the empty patch that serves to retain the liquid in a moist environment.
DermaPrep, conceived as an alternative to syringes, is designed for the targeted delivery of molecules via the stratum corneum to the following tissues:
- the lymphoid tissue for vaccines formulated with Nanomedicines
Importantly, sensitive substances that cannot be formulated together with patches can now be topically administered. Medications can be stored frozen or lyophilized just prior to use and doses can be adjusted by volume, concentration, patch size, or number of patches used.
Substances are administered via a simple, three step process.
First, the skin is cleansed and exfoliated using the supplied sponge and medical tape. The advantage gained is improved penetration of substances through skin. Next, the Transparent Film Dressing (Patch) is applied, providing a container that keeps medication in contact with the prepared skin surface. The dimensions of the patch can be adapted to any size desired. And in the third, final step the active substance of the treatment is applied under the patch using a needle-free syringe or an applicator equipped plastic bottle.
DermaPrep clinical data has been obtained via administration of pDNA-encoded antigens formulated to nanoparticles. Genetic Immunity's proprietary Nanomedicine formulation (antigens, pDNA, proteins, peptides, etc.) is delivered topically with DermaPrep, targeting the body's professional antigen presenting cells, the lymph node dendritic cells, to induce potent immune responses.
Through the Company's ongoing clinical trials program, DermaPrep has amassed significant quantities of data proving its preclinical and clinical safety, tolerability and immunogenicity. As of October 2008, DermaPrep has been granted a CE mark (marketing approval) for medical device in Europe, with US certification underway.
To expand the unique delivery potential of DermaPrep it is now available for licensing worldwide.
For specific delivery situations, to receive our detailed product literature, to schedule a consultation or for general information please visit the Company’s official website at http://www.geneticimmunity.com or contact Zsolt Lisziewicz directly at +36-1-272-0364
At Genetic Immunity:
Source: Power of the Dream Ventures, Inc.